Effect of ethnicity and chemotherapy (mFOLFOX6) on zolbetuximab pharmacokinetics in patients with claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ).

被引：0
|
作者：
Lee, Keun-Wook
Klempner, Samuel J.
Yang, Jianning
Desai, Amit
Yamada, Akihiro
Ueno, Yoko
Wojtkowski, Tomasz
Park, Jung Wook
Pavese, Janet
Loupakis, Fotios
Bang, Yung-Jue
Shitara, Kohei
机构：
[1] Seoul Natl Univ, Bundang Hosp, Coll, Seongnam, South Korea
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Astellas Pharma Global Dev, Northbrook, IL USA
[4] Astellas Pharma Global Dev Inc, Northbrook, IL USA
[5] Univ Pisana, Univ Azienda Osped, Pisa, Italy
[6] Seoul Natl Univ Hosp, Seoul, South Korea
[7] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e16078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16078
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Health-related quality of life (hrqol) in patients with claudin18 isoform 2-positive (CLDN18.2+) locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma: Results from SPOTLIGHT and
    Lordick, F.
    Van Cutsem, E.
    Shitara, K.
    Xu, R-H.
    Ajani, J. A.
    Shah, M. A.
    Oh, M.
    Ganguli, A.
    Rhoten, S.
    Bhattacharya, P.
    Matsangou, M.
    Park, J. W.
    Kang, Y-K.
    ANNALS OF ONCOLOGY, 2023, 34 : S860 - S861
  • [32] Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
    Shitara, Kohei
    Xu, Rui-Hua
    Ajani, Jaffer A.
    Moran, Diarmuid
    Guerrero, Abraham
    Li, Ran
    Pavese, Janet
    Matsangou, Maria
    Bhattacharya, Pranob
    Ueno, Yoko
    Wang, Xuewei
    Shah, Manish A.
    GASTRIC CANCER, 2024, 27 (05) : 1058 - 1068
  • [33] Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER22, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Shitara, Kohei
    Van Cutsem, Eric
    Lordick, Florian
    Enzinger, Peter C.
    Ilson, David H.
    Shah, Manish A.
    Xu, Rui-Hua
    Lonardi, Sara
    Yamaguchi, Kensei
    Hung, Yi-Ping
    Kukielka-Budny, Bozena
    Bhattacharya, Pranob P.
    Matsangou, Maria
    Li, Ran
    Moran, Diarmuid Martin
    Ranganath, Radhika
    Pophale, Rupesh
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial (vol 401, pg 1655, 2023)
    Shitara, K.
    Lordick, F.
    Bang, Y-J
    LANCET, 2023, 402 (10398): : 290 - 290
  • [35] Zolbetuximab plus CAPOX versus CAPOX in first-line treatment of claudin18.2+/HER2- advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study
    Shah, Manish A.
    Ajani, Jaffer A.
    Al-Batran, Salah-Eddin
    Bang, Yung-Jue
    Catenacci, Daniel V. T.
    Enzinger, Peter C.
    Ilson, David H.
    Kim, Sunnie S.
    Lordick, Florian
    Shitara, Kohei
    Van Cutsem, Eric
    Arozullah, Ahsan
    Raizer, Jeffrey J.
    Park, Jung Wook
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [36] SHARED: Efficacy and safety of sintilimab in combination with concurrent chemoradiotherapy (cCRT) in patients with locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma.
    Wei, Jia
    Lu, Xiaofeng
    Liu, Qin
    Fu, Yao
    Liu, Song
    Yang, Ju
    Wang, Meng
    Zheng, Liming
    Yang, Yang
    Fan, Xiangshan
    Zhao, Yang
    Guan, Wenxian
    Liu, Baorui
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
    Bang, Y-J.
    Shen, L.
    Kang, Y-K.
    Chao, Y.
    Soo, H. H. F.
    Sunpaweravong, P.
    Moran, D.
    Guerrero, A.
    Li, R.
    Pavese, J.
    Matsangou, M.
    Bhattacharya, P.
    Shitara, K.
    Xu, R-H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1527 - S1528
  • [38] GLOW: Randomized phase III study of zolbetuximab plus CAPOX compared with placebo plus CAPOX as first-line treatment of patients with CLD18.2+/HER2- locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Shah, M.
    Ajani, J. A.
    Al-Batran, S-E.
    Bang, Y-J.
    Catenacci, D. V.
    Enzinger, P.
    Ilson, D.
    Kim, S.
    Lordick, F.
    Shitara, K.
    Van Cutsem, E.
    Arozullah, A.
    Park, J. W.
    Xu, R-H.
    ANNALS OF ONCOLOGY, 2019, 30 : 322 - 322
  • [39] A phase II study of capecitabine-oxaliplatin and cetuximab in patients (pts) with advanced/metastatic gastric cancer (G) or gastroesophageal junction (GEJ) adenocarcinoma
    Iqbal, Syma
    El-Khoueiry, Anthony B.
    Yang, Dongyun
    Paez, David
    Duddalwar, Vinay
    Zhang, Wu
    Agafitei, Raluca Dana
    Lujan, Ramona
    Cole, Sarah
    Ning, Yan
    El-Khoueiry, Rita
    Loupakis, Fotios
    Wakatsuki, Takeru
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] Management of nausea and vomiting (N/V) following first-line (1L) zolbetuximab plus chemotherapy treatment in claudin-18.2 (CLDN18.2)+, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Analysis from the phase 3 SPOTLIGHT and GLOW studies.
    Shitara, Kohei
    Pophale, Rupesh
    Matsangou, Maria
    Park, Jung Wook
    Oh, Mok
    Bhattacharya, Pranob P.
    Ranganath, Radhika
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 372 - 372
12345